In a report released yesterday, Andrew Tsai from Jefferies maintained a Buy rating on Annexon Biosciences (ANNX – Research Report), with a price target of $10.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andrew Tsai has given his Buy rating due to a combination of factors that highlight Annexon Biosciences’ potential for growth and value creation. The company is trading at cash value despite having promising catalysts lined up for 2025-2026. One key opportunity is the ANX005, a C1q antibody, which is expected to meet with the FDA regarding Guillain-Barré Syndrome (GBS) and could lead to a Biologics License Application (BLA) filing. The potential market for GBS is significant, with an estimated opportunity of $300-500 million or more.
Additionally, Annexon is advancing its pipeline with ANX1502, an oral C1s inhibitor, which could expand into autoimmune disorders with a market potential exceeding $1 billion. The company is also progressing with ANX007 for geographic atrophy in eye disease, with Phase III enrollment expected to complete in 2025 and data anticipated in 2026. These developments, along with positive clinical data and strategic FDA interactions, underpin Tsai’s confidence in the stock’s potential upside.
Tsai covers the Healthcare sector, focusing on stocks such as Annexon Biosciences, Sarepta Therapeutics, and Supernus Pharmaceuticals. According to TipRanks, Tsai has an average return of -0.1% and a 47.11% success rate on recommended stocks.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $14.00 price target.